BIOMAT Database Logo BIOMAT Database Logo

Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. 1998

T J Walsh, and J W Hiemenz, and N L Seibel, and J R Perfect, and G Horwith, and L Lee, and J L Silber, and M J DiNubile, and A Reboli, and E Bow, and J Lister, and E J Anaissie
Infectious Diseases Section, National Cancer Institute, Bethesda, Maryland 20892, USA.

The safety and antifungal efficacy of amphotericin B lipid complex (ABLC) were evaluated in 556 cases of invasive fungal infection treated through an open-label, single-patient, emergency-use study of patients who were refractory to or intolerant of conventional antifungal therapy. All 556 treatment episodes were evaluable for safety. During the course of ABLC therapy, serum creatinine levels significantly decreased from baseline (P < .02). Among 162 patients with serum creatinine values > or = 2.5 mg/dL at the start of ABLC therapy (baseline), the mean serum creatinine value decreased significantly from the first week through the sixth week (P < or = .0003). Among the 291 mycologically confirmed cases evaluable for therapeutic response, there was a complete or partial response to ABLC in 167 (57%), including 42% (55) of 130 cases of aspergillosis, 67% (28) of 42 cases of disseminated candidiasis, 71% (17) of 24 cases of zygomycosis, and 82% (9) of 11 cases of fusariosis. Response rates varied according to the pattern of invasive fungal infection, underlying condition, and reason for enrollment (intolerance versus progressive infection). These findings support the use of ABLC in the treatment of invasive fungal infections in patients who are intolerant of or refractory to conventional antifungal therapy.

UI MeSH Term Description Entries
D008297 Male Males
D009181 Mycoses Diseases caused by FUNGI. Fungus Diseases,Fungal Diseases,Fungal Infections,Fungus Infections,Disease, Fungal,Disease, Fungus,Diseases, Fungal,Diseases, Fungus,Fungal Disease,Fungal Infection,Fungus Disease,Fungus Infection,Infection, Fungal,Infection, Fungus,Infections, Fungal,Infections, Fungus
D010713 Phosphatidylcholines Derivatives of PHOSPHATIDIC ACIDS in which the phosphoric acid is bound in ester linkage to a CHOLINE moiety. Choline Phosphoglycerides,Choline Glycerophospholipids,Phosphatidyl Choline,Phosphatidyl Cholines,Phosphatidylcholine,Choline, Phosphatidyl,Cholines, Phosphatidyl,Glycerophospholipids, Choline,Phosphoglycerides, Choline
D010715 Phosphatidylglycerols A nitrogen-free class of lipids present in animal and particularly plant tissues and composed of one mole of glycerol and 1 or 2 moles of phosphatidic acid. Members of this group differ from one another in the nature of the fatty acids released on hydrolysis. Glycerol Phosphoglycerides,Monophosphatidylglycerols,Phosphatidylglycerol,Phosphatidyl Glycerol,Glycerol, Phosphatidyl,Phosphoglycerides, Glycerol
D002177 Candidiasis Infection with a fungus of the genus CANDIDA. It is usually a superficial infection of the moist areas of the body and is generally caused by CANDIDA ALBICANS. (Dorland, 27th ed) Candida Infection,Moniliasis,Candida Infections,Candidiases,Infection, Candida,Moniliases
D003404 Creatinine Creatinine Sulfate Salt,Krebiozen,Salt, Creatinine Sulfate,Sulfate Salt, Creatinine
D003453 Cryptococcosis Fungal infection caused by genus CRYPTOCOCCUS. C gattii Infection,C neoformans Infection,C. gattii Infection,C. neoformans Infection,Cryptococcus Infection,Cryptococcus Infections,Cryptococcus gattii Infection,Torulosis,Cryptococcus neoformans Infection,C gattii Infections,C neoformans Infections,C. gattii Infections,C. neoformans Infections,Cryptococcoses,Cryptococcus gattii Infections,Cryptococcus neoformans Infections,Infection, C gattii,Infection, C neoformans,Infection, C. gattii,Infection, C. neoformans,Infection, Cryptococcus,Infection, Cryptococcus gattii,Infection, Cryptococcus neoformans,Infections, C gattii,Infections, C. neoformans,Toruloses
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

T J Walsh, and J W Hiemenz, and N L Seibel, and J R Perfect, and G Horwith, and L Lee, and J L Silber, and M J DiNubile, and A Reboli, and E Bow, and J Lister, and E J Anaissie
Efficacy and safety of amphotericin B lipid complex in 548 children and adolescents with invasive fungal infections.
February 2005, The Pediatric infectious disease journal,
T J Walsh, and J W Hiemenz, and N L Seibel, and J R Perfect, and G Horwith, and L Lee, and J L Silber, and M J DiNubile, and A Reboli, and E Bow, and J Lister, and E J Anaissie
Amphotericin B lipid complex for the treatment of invasive fungal infections.
November 2003, Expert opinion on pharmacotherapy,
T J Walsh, and J W Hiemenz, and N L Seibel, and J R Perfect, and G Horwith, and L Lee, and J L Silber, and M J DiNubile, and A Reboli, and E Bow, and J Lister, and E J Anaissie
Efficacy and safety of amphotericin B lipid complex injection (ABLC) in solid-organ transplant recipients with invasive fungal infections.
August 2000, Clinical transplantation,
T J Walsh, and J W Hiemenz, and N L Seibel, and J R Perfect, and G Horwith, and L Lee, and J L Silber, and M J DiNubile, and A Reboli, and E Bow, and J Lister, and E J Anaissie
Amphotericin B lipid complex to treat invasive fungal infections in cancer patients: report of efficacy and safety in 20 patients.
January 1995, Chemotherapy,
T J Walsh, and J W Hiemenz, and N L Seibel, and J R Perfect, and G Horwith, and L Lee, and J L Silber, and M J DiNubile, and A Reboli, and E Bow, and J Lister, and E J Anaissie
Efficacy of amphotericin B lipid complex in the treatment of invasive fungal infections in immunosuppressed paediatric patients.
February 2001, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
T J Walsh, and J W Hiemenz, and N L Seibel, and J R Perfect, and G Horwith, and L Lee, and J L Silber, and M J DiNubile, and A Reboli, and E Bow, and J Lister, and E J Anaissie
Retrospective analysis of the dosage of amphotericin B lipid complex for the treatment of invasive fungal infections.
November 1999, Pharmacotherapy,
T J Walsh, and J W Hiemenz, and N L Seibel, and J R Perfect, and G Horwith, and L Lee, and J L Silber, and M J DiNubile, and A Reboli, and E Bow, and J Lister, and E J Anaissie
Amphotericin B lipid complex in the management of invasive fungal infections in immunocompromised patients.
November 2011, Clinical drug investigation,
T J Walsh, and J W Hiemenz, and N L Seibel, and J R Perfect, and G Horwith, and L Lee, and J L Silber, and M J DiNubile, and A Reboli, and E Bow, and J Lister, and E J Anaissie
Amphotericin B lipid complex: treatment of invasive fungal infections in patients refractory to or intolerant of amphotericin B deoxycholate.
December 2008, Therapeutics and clinical risk management,
T J Walsh, and J W Hiemenz, and N L Seibel, and J R Perfect, and G Horwith, and L Lee, and J L Silber, and M J DiNubile, and A Reboli, and E Bow, and J Lister, and E J Anaissie
Budget impact analysis of liposomal amphotericin B and amphotericin B lipid complex in the treatment of invasive fungal infections in the United States.
February 2014, Applied health economics and health policy,
T J Walsh, and J W Hiemenz, and N L Seibel, and J R Perfect, and G Horwith, and L Lee, and J L Silber, and M J DiNubile, and A Reboli, and E Bow, and J Lister, and E J Anaissie
Pharmacoeconomic analysis of amphotericin B lipid complex versus liposomal amphotericin B in the treatment of fungal infections.
January 2004, PharmacoEconomics,
Copied contents to your clipboard!